Fundraising FoxPfizer Ventures — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityCasdin CapitalChiesi VenturesPappas Capital+7 more
Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.
BiotechHealthtechLeuven, BE
Federico Grossi(Clinical Advisor & Acting CMO)
Co-investorsDroia VenturesVIBPfizer Venture Investments
Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.
BiotechDigital HealthMedical DevicesWaltham, US
Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)
Co-investorsMatrix Capital ManagementPfizer Venture InvestmentsSR One Capital ManagementVertex Ventures HCBioHealth Innovation, Inc.Takeda Ventures
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)
Co-investorsKeshif VenturesPappas CapitalPfizer Venture InvestmentsHBM Healthcare InvestmentsPappas CapitalSoleus Capital
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)in
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresAlexandria+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.